Opportunities for biotechs in precision medicine: bringing important new therapies to patients and value to the company

June 16, 2020

The past 20 years have seen a transformation in the field of precision medicine. Precision medicine has not only impacted drug development, but also drug discovery and disease diagnosis, allowing scientists to use molecular characteristics to define diseases and moving diagnosis away from clinical signs and symptoms. For biotech companies, this new landscape holds tremendous promise for innovation – for new drug targets, newly designed drugs, new technologies for drug delivery, and engineered cell or gene therapies.

In this article, Angela Qu, MD, PhD, Vice President, and Arlene Hughes, PhD, Senior Director from Parexel's Translational Medicine Group offer insights about what biotechs should be thinking about from the start to utilize this approach to help bring innovation and new therapies to more patients.  

Previous Article
On-demand webinar: Value of real-world evidence and synthetic control arms
On-demand webinar: Value of real-world evidence and synthetic control arms

Learn about the benefits that real-world evidence (RWE) can bring to small & mid-size biotech companies.

Next Article
COVID-19 and the impact on pediatric clinical trials
COVID-19 and the impact on pediatric clinical trials

The COVID-19 global pandemic has had a significant impact on the conduct of pediatric and adult clinical dr...

Contact Us with your Biotech needs!

Email Us